Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts.
human papillomavirus
local therapy
pediatric dermatology
vaccines
verruca
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
14
06
2023
received:
17
04
2023
accepted:
10
07
2023
medline:
6
11
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Human papillomavirus (HPV) is ubiquitously distributed in the population worldwide and its most frequent clinical presentation is cutaneous warts. Despite various treatment options currently available, many patients experience persistent and refractory disease. We sought to evaluate the clinical effectiveness and safety profile of intralesional HPV 9-valent vaccine for the treatment of recalcitrant warts. A retrospective study was performed for all cases of cutaneous warts treated with intralesional 9-valent HPV vaccine between January 2017 and March 2021. Epidemiologic, clinical, and treatment data, including safety and effectiveness scores, were reviewed. Our cohort was composed of 20 patients: 13 adults and seven children. Twelve patients (60%) displayed a complete response whereas 8 patients (40%) showed a partial response. Older age was associated with a better response to treatment, while a history of laser therapy was associated with a worse prognosis. Adverse events were local, transient, and negligible. No systemic adverse effects were reported. Intralesional 9-valent HPV vaccine may be considered for the treatment of recalcitrant cutaneous warts. Controlled studies are required to confirm these results.
Identifiants
pubmed: 37501372
doi: 10.1111/1346-8138.16905
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1373-1380Informations de copyright
© 2023 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3-12.
Tyring SK. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J Am Acad Dermatol. 2000;43(1 pt 2):S18-26.
Tschandl P, Rosendahl C, Kittler H. Cutaneous human papillomavirus infection: manifestations and diagnosis. Curr Probl Dermatol 2014;45:92-7.
Syrjänen S. Oral manifestations of human papillomavirus infections. Eur J Oral Sci. 2018;126 suppl 1(suppl suppl 1):49-66.
Zur HH. Papillomavirus infection - a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55-78.
Soenjoyo KR, Chua BW, Wee LW, Koh MJ, Ang SB. Treatment of cutaneous viral warts in children: a review. Dermatol Ther. 2020;33:e14034.
Dasher DA, Burkhart CN, Morrell DS. Immunotherapy for childhood warts. Pediatr Ann. 2009;38:373-9.
Ki M, Choi HY, Han M, Oh JK. The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015. Vaccine. 2018;36:4633-40.
Tyros G, Mastraftsi S, Gregoriou S, Nicolaidou E. Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination. Int J STD AIDS. 2020;9:4-13.
de Oliveira CM, Fregnani JH, Villa LL. HPV vaccine: updates and highlights. Acta Cytol. 2019;63:159-68.
Waldman A, Whiting D, Rani M, Alam M. HPV vaccine for treatment of recalcitrant cutaneous warts in adults: a retrospective cohort study. Dermatol Surg. 2019;45:1739-41.
Abeck D, Fölster-Holst R. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children. Acta Derm Venereol. 2015;95:1017-9.
Kuan LY, Chua SH, Pan JY, Yew YW, Tan WP. The quadrivalent human papillomavirus vaccine in recalcitrant non-genital warts: a retrospective study. Ann Acad Med Singapore. 2020;49:749-55.
Pham CT, Juhasz M, Sung CT, Mesinkovska NA. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: a literature review. J Am Acad Dermatol. 2020;82:202-12.
Yang MY, Son JH, Kim GW, Kim HS, Ko HC, Kim MB, et al. Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients. J Dermatol Treat. 2018;30:1-5.
Marei A, Nofal A, Alakad R, Abdel-Hady A. Combined bivalent human papillomavirus vaccine and Candida antigen versus Candida antigen alone in the treatment of recalcitrant warts. J Cosmet Dermatol. 2020;19:758-62.
Smith SP, Baxendale HE, Sterling JC. Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. Clin Exp Dermatol. 2017;42:306-8.
Nofal A, Marei A, Ibrahim AM, Nofal E, Nabil M. Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts. J Am Acad Dermatol. 2020;82:94-100.
Mohammed YF, Ibrahim HS, Elbarbary MA, Elsaie ML. Comparative study of intralesional tuberculin protein purified derivative (PPD) and intralesional measles, mumps, rubella (MMR) vaccine for multiple resistant warts. J Cosmet Dermatol. 2021;20:868-74.
Fields JR, Saikaly SK, Schoch JJ. Intralesional immunotherapy for pediatric warts: a review. Pediatr Dermatol. 2020;37:265-71.
Daniel BS, Murrell DF. Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papillomavirus vaccine. JAMA Dermatol 2013;149:370-2.
Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937-49.
Ferguson SB, Gallo ES. Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult. JAAD Case Rep. 2017;3:367-9.
Wyant WA, Burke GW, Ioannides T, Nichols AJ. Systemic 9-valent human papillomavirus vaccine for recalcitrant common cutaneous warts in preparation for renal transplant. JAAD Case Rep. 2022;23:62-3.
Kost Y, Zhu TH, Blasiak RC. Clearance of recalcitrant warts in a pediatric patient following administration of the nine-valent human papillomavirus vaccine. Pediatr Dermatol. 2020;37:748-9.
Aldahan AS, Mlacker S, Shah VV, Kamath P, Alsaidan M, Samarkandy S, et al. Efficacy of intralesional immunotherapy for the treatment of warts: a review of the literature. Dermatol Ther. 2016;29:197-207.
Surani AS, Un R, Marfatia Y. Efficacy of intralesional measles mumps rubella vaccine in the treatment of verruca vulgaris: an interventional study. Cureus. 2023;15:e34338.